Avadel Announces Preliminary 2024 Results and 2025 Commercial Priorities to Accelerate the LUMRYZ Launch
08 janv. 2025 16h15 HE
|
Avadel Pharmaceuticals plc
-- Approximately $50.0 million of net revenue from sales of LUMRYZ™ estimated for the fourth quarter, a greater than 150% increase over $19.5 million for the comparable period in 2023 -- --2,500...
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
06 janv. 2025 16h05 HE
|
Avadel Pharmaceuticals plc
DUBLIN, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee...
Avadel Pharmaceuticals to Provide a Corporate Update and Preliminary Fourth Quarter and Full Year 2024 Financial Highlights on January 8
03 janv. 2025 08h00 HE
|
Avadel Pharmaceuticals plc
DUBLIN, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will...
Results from Social Listening Analysis and Survey of People with Narcolepsy Uncover Real-Life Challenges with Twice-Nightly Oxybate Therapy
11 déc. 2024 08h00 HE
|
Avadel Pharmaceuticals plc
– Findings published in Brain Sciences showed missed doses and potential for injury when waking to take a second dose among the key challenges – DUBLIN, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Avadel...
Avadel Pharmaceuticals to Present at the Jefferies London Healthcare Conference
13 nov. 2024 08h00 HE
|
Avadel Pharmaceuticals plc
DUBLIN, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of...
Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2024 Financial Results
12 nov. 2024 07h00 HE
|
Avadel Pharmaceuticals plc
-- Generated $50.0 million in net revenue from sales of LUMRYZ™ -- --2,300 patients on LUMRYZ as of September 30th, including 700 patients that initiated therapy in the quarter -- -- Received...
Avadel Pharmaceuticals to Provide a Corporate Update and Report Third Quarter 2024 Financial Results on November 12
04 nov. 2024 08h00 HE
|
Avadel Pharmaceuticals plc
DUBLIN, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will...
Avadel Pharmaceuticals Announces Favorable Ruling in Administrative Procedure Act Litigation
31 oct. 2024 07h00 HE
|
Avadel Pharmaceuticals plc
DUBLIN, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced that yesterday, the...
Avadel Pharmaceuticals and nference Announce Publication of Real-World Data in Sleep Advances
24 oct. 2024 08h00 HE
|
Avadel Pharmaceuticals plc
DUBLIN, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, and nference, a health tech...
Avadel Pharmaceuticals Announces FDA Approval of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension (CIII) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older with Narcolepsy
17 oct. 2024 09h41 HE
|
Avadel Pharmaceuticals plc
-- LUMRYZ is the only FDA-approved once-at-bedtime oxybate treatment for cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy— -- Granted Orphan Drug...